Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Extends Continuous Marketing Application Pilot 2 Deadline Again

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA extends continuous marketing application Pilot 2 deadline again. At least eight CDER divisions have chosen INDs for the fast-track pilot program, with eight remaining. Applications will be accepted until Dec. 31

You may also be interested in...



Neurochem Fibrillex misses endpoint

Neurochem's amyloid A amyloidosis agent Fibrillex fails to meet its primary endpoint in a Phase II/III trial, the firm says April 18. Preliminary results from the two-year, 183-patient study found there were 13.4% more patients on Fibrillex than placebo who remained stable or improved (p=0.06). The primary endpoint required a 20% absolute difference in the number of stabilized/improved patients versus placebo (p<0.01). Neurochem, which previously projected a 2005 NDA submission, says it remains committed to Fibrillex and will discuss its complete Phase II/III findings with FDA. Fibrillex was accepted into FDA's continuous marketing application Pilot 2 program by the cardio-renal division in July 2004 (1Pharmaceutical Approvals Monthly December 2004, p. 17)...

HGS Lymphostat-B Is 1 Of 7 Agents Selected For FDA’s Pilot 2 CMA Program

FDA has selected Human Genome Sciences’ lupus biologic Lymphostat-B for the continuous marketing application (CMA) Pilot 2 program, HGS announced March 4.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS002723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel